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Abstract
Aims/hypothesis The aim of this study was to determine
whether oral dosing with N-acetylcysteine (NAC) increases
intraplatelet levels of the antioxidant, glutathione (GSH),
and reduces platelet–monocyte conjugation in blood from
patients with type 2 diabetes.
Methods In this placebo-controlled randomised crossover
study, the effect of oral NAC dosing on platelet–monocyte
conjugation and intraplatelet GSH was investigated in
patients with type 2 diabetes (eligibility criteria: men or
post-menopausal women with well-controlled diabetes
(HbA1c<10%), not on aspirin or statins). Patients (n014; age
range 43–79 years, HbA1c06.9±0.9% [52.3±10.3 mmol/mol])
visited the Highland Clinical Research Facility, Inverness, UK
on day 0 and day 7 for each arm of the study. Blood was
sampled before and 2 h after oral administration of placebo or
NAC (1,200 mg) on day 0 and day 7. Patients received placebo
or NAC capsules for once-daily dosing on the intervening days.
The order of administration of NAC and placebo was allocated
by a central office and all patients and research staff involved in
the study were blinded to the allocation until after the study was
complete and the data fully analysed. The primary outcome for
the study was platelet–monocyte conjugation.
Results Oral NAC reduced platelet–monocyte conjugation
(from 53.1±4.5% to 42.5±3.9%) at 2 h after administration
and the effect was maintained after 7 days of dosing. Intra-
platelet GSH was raised in individuals with depleted GSH
and there was a negative correlation between baseline intra-
platelet GSH and platelet–monocyte conjugation. There
were no adverse events.
Conclusions/interpretation The NAC-induced normalisa-
tion of intraplatelet GSH, coupled with a reduction in plate-
let–monocyte conjugation, suggests that NAC might help to
reduce atherothrombotic risk in type 2 diabetes.
Funding: Chief Scientist Office (CZB/4/622), Scottish
Funding Council, Highlands & Islands Enterprise and Eu-
ropean Regional Development Fund.
Trial registration: isrctn.org ISRCTN89304265
Keywords N-acetylcysteine . Antioxidative treatment .
Atherothrombosis . Glutathione . Monocyte . Platelet .
Therapeutics . Type 2 diabetes
Electronic supplementary material The online version of this article
(doi:10.1007/s00125-012-2685-z) contains peer-reviewed but unedited
supplementary material, which is available to authorised users.
A. T. Treweeke : T. J. Winterburn : I. Mackenzie :
I. L. Megson (*)
Free Radical Research Facility, Department of Diabetes &
Cardiovascular Science, University of the Highlands & Islands,
Centre for Health Science,
Inverness IV2 3JH, UK
e-mail: ian.megson@uhi.ac.uk
F. Barrett :G. F. Rushworth
NHS Highland, Highland Clinical Research Facility, University of
the Highlands & Islands, Centre for Health Science,
Inverness, UK
C. Barr : S. M. MacRury
Highland Clinical Research Facility, University of the Highlands
& Islands, Centre for Health Science,
Inverness, UK
I. Dransfield
MRC Centre for Inflammation Research,
Queen’s Medical Research Institute, University of Edinburgh,
Edinburgh, UK
S. M. MacRury
Department of Diabetes and Cardiovascular Science,
University of the Highlands & Islands, Centre for Health Science,
Inverness, UK
Diabetologia (2012) 55:2920–2928
DOI 10.1007/s00125-012-2685-z
Abbreviations
eGFR Estimated GFR
NAC N-acetylcysteine
NO Nitric oxide
PAI-1 Plasminogen activator inhibitor-1
ROS Reactive oxygen species
SBD-F 7-Fluoro-2,1,3-benzoxadiazole-4-sulfonate
tGSH Total glutathione
Introduction
Oxidative stress is implicated in both the aetiology and the
cardiovascular complications of type 2 diabetes [1–5]. In-
creased reactive oxygen species (ROS) generation is a feature
of platelets in type 2 diabetes [6] and contributes to platelet
hyperaggregability associated with the disease [7, 8]. Oxida-
tive stress is also implicit in endothelial dysfunction associated
with atherosclerosis and subsequent thrombotic complications
[9]. Since the realisation that aspirin fails to show sufficient
clinical benefit in primary prevention of cardiovascular events
in diabetes to merit its universal prescription to this group of
patients [10, 11], there is renewed urgency in finding alterna-
tives. Given the central role of oxidative stress in both diabetes
and the resultant cardiovascular complications, antioxidant
intervention is a promising therapeutic option that could spe-
cifically target atherothrombotic processes.
Glutathione (GSH) is an abundant, key endogenous anti-
oxidant that is depressed in platelets from patients with type 2
diabetes, contributing to hyperaggregability [12]. Intramuscu-
lar GSH administration increases levels of protective nitric
oxide (NO) in platelets from patients with type 2 diabetes,
with a concomitant decrease in plasma levels of the fibrino-
lytic inhibitor, plasminogen activator inhibitor-1 (PAI-1) [13].
However, GSH is a poor candidate for oral therapy because of
peptide digestion in the stomach and poor membrane penetra-
tion. N-acetylcysteine (NAC), is a well-recognised intrave-
nous therapy used to redress acute GSH depletion in
overdosage with paracetamol (known as acetaminophen in
the USA and Canada) [14]. NAC is currently under investi-
gation for its antioxidant benefits in a range of clinical con-
ditions [15–20], although there are some doubts about its
efficacy, particularly in contrast-induced nephropathy [21].
In the diabetes arena, oral NAC has been shown to
improve endothelial function in a rat model of diabetes
[22] and to reduce endothelial activation, oxidative stress
markers [23] and blood pressure [24] in patients with type 2
diabetes. Very high concentrations (3 mmol/l) augment NO-
mediated inhibition of platelet aggregation in blood from
obese patients in vitro [25]. Our own previous studies in
vitro indicated that much lower concentrations of NAC,
which are achievable with oral dosing (10–100 μmol/l),
inhibit platelet function in blood from healthy volunteers
[26] and in patients with type 2 diabetes [27]. This effect
was associated with increased intraplatelet GSH, inhibition
of oxidative stress and increased levels of NO metabolites.
Here, we tested the hypothesis that oral NAC dosing
causes acute (2 h) inhibition of platelet–monocyte conjuga-
tion and microparticle count—both recognised as markers
of cardiovascular risk—in blood from patients with type 2
diabetes, and that the effect is maintained after daily dosing
for 7 days in free-living individuals. Furthermore, we sought
to explore the association between the effectiveness of NAC
and baseline intraplatelet GSH.
Methods
Study participants Eligible patients with type 2 diabetes
(Tables 1 and 2) were recruited through local general practi-
tioners. All patients gave written informed consent in line
with International Conference on Harmonisation Good Clin-
ical Practice guidelines. At an initial screening visit, venous
blood (9 ml) was collected from the antecubital fossa into
lithium heparin-containing tubes (Sarstedt, Leicester, UK) to
screen lipid and renal status (Piccolo Lipid and Renal Pan-
els, respectively; Abaxis, Darmstadt, Germany); a finger-
prick blood sample was obtained for HbA1c determination
(DCA 2000+ Analyser; Bayer, Newbury, UK). Individuals
meeting the study inclusion criteria returned within 2 weeks
for commencement of the clinical study.
Inclusion criteria for the study were as follows: (1) men or
post-menopausal women with type 2 diabetes (to avoid the
variability of platelet count and behaviour during themenstrual
cycle); (2) those not receiving aspirin (aspirin was withdrawn
at least 10 days in advance of the first visit and throughout the
study period); (3) those not receiving lipid-lowering therapy—
where necessary, statins were withdrawn 1 month in advance
of the first visit and throughout the study period.
Exclusion criteria for the study were as follows: (1) very
poorly controlled diabetes (HbA1c >10% [86 mmol/mol]); (2)
significant hypertriacylglycerolaemia (triacylglycerols
>4 mmol/l); (3) renal disease, defined by estimated GFR
(eGFR) <40 ml/min; (4) current or recently stopped (within
last 6 months) smokers; (5) patients receiving other antiplate-
let therapy (e.g. clopidogrel, dipyridamole) or lipid-lowering
therapy, or where patients were unable or unwilling to stop
Table 1 Patient
characteristics
Data are expressed as
mean±SD (n014)
Characteristic
Age (years) 63.9±10.1
Sex (male/female) 9:5
BMI (kg/m2) 33.1±5.7
HbA1c (%) 6.9±0.90
HbA1c (mmol/mol) 52.3±10.3
Cholesterol (mmol/l) 4.7±1.1
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therapy for the duration of study participation; (6) current use
of tetracycline antibiotics or cough suppressants; (7) patients
with asthma, because of the low but increased risk of bron-
chospasm and the increased frequency of anaphylactoid reac-
tions to NAC in asthma suffers.
Study design
Patients were randomised to receive either NAC (1,200mg) or
placebo daily for a total of 8 days: both researchers and
patients were blinded in this crossover study. On day 0,
patients attended the Highland Clinical Research Facility be-
tween 09:00 and 09:30 hours, after an overnight fast to min-
imise diet-induced and diurnal variations in platelet reactivity.
A baseline venous blood sample (90 ml) was drawn from the
antecubetal fossa using a 21G butterfly device and syringe
before oral administration of NAC 1,200 mg (2×600 mg
capsules) or placebo. The butterfly was flushed with normal
saline after initial sampling and 2 h later, having discarded the
first 2 ml blood, a second blood sample was taken in the same
manner as the first and the patients were provided with a 6-day
supply of NAC or placebo capsules for once-daily self-
administration. On day 7 of the study, patients returned after
an overnight fast for a blood withdrawal before and at 2 h after
their final NAC or placebo dose in this arm of the study
(protocol identical to day 0). Patients received a light breakfast
of buttered toast and water immediately after baseline meas-
ures on study visits. Awashout period of at least 1 week was
allowed before patients returned for the crossover, which
followed the same protocol as the first arm of the study. The
study design is summarised in Fig. 1 and the recruitment,
enrolment and randomisation process is summarised in elec-
tronic supplementary material (ESM) Fig. 1.
Ethics approval Clinical Trial Authorisation was granted by
Medicines & Healthcare Products Regulatory Agency,
Eudract number 2008-001620 and the study was approved
by the North of Scotland Research Ethics Committee, study
number 06/S0901/39. Clinical trial registration number:
ISRCTN89304265.
Blood samples Consistent blood sampling and handling is
essential for meaningful results for the proposed flow
cytometry assays in particular. Drawn blood was rapidly trans-
ferred to tubes containing EDTA, trisodium citrate or heparin
(Monovette) and gently inverted several times to mix. Hepari-
nised blood was used for platelet–monocyte conjugation and
microparticle experiments, citrated plasma for PAI-1 measures
and EDTA for platelet total GSH (tGSH) measurement.
Platelet–monocyte conjugation Platelet–monocyte conju-
gates were measured by flow cytometry detection of dual-
stained, whole blood samples. Briefly, 100 μl of heparinised
whole blood was incubated with CD14-FITC and CD41-PE-
Cy5 antibodies, or the appropriate isotype controls, for 15 min.
After addition of 1ml FACS lysing solution (BectonDickinson,
Oxford, UK), the cells were incubated for a further 15 min and
then immediately analysed for conjugates using a FACSCalibur
flow cytometer (Becton Dickinson). Platelet–monocyte conju-
gates were identified as CD14/CD41-positive events.
Microparticles Microparticles were prepared from heparinised
whole blood. Samples were centrifuged at 500 g for 5 min, the
plasma was removed and centrifuged at 5,000 g for 5 min; this
was repeated twice to remove any remaining cells. Next, 1 ml
of this plasma was further centrifuged at 16,000 g for 5 min,
and the microparticle pellet was washed with filtered FACS
flow (Becton Dickinson), centrifuged again at 16,000 g and
then resuspended in 0.5 ml FACS flow spiked with 3 μm
polystyrene latex beads (Sigma Aldrich, Poole, UK). These
purified microparticles were acquired through a FACSCalibur
flow cytometer and their numbers calculated relative to the
known, fixed number of beads acquired at the same time.
PAI-1 antigen and activity Plasma was prepared by centri-
fugation of citrated blood at 1,000 g at room temperature for
10 min and then frozen at −70°C. PAI-1 antigen and PAI-1
activity were both measured using Zymutest ELISA assay
kits (Hyphen BioMed, Paris, France) according to the man-
ufacturer’s instructions.
tGSH determination tGSH was measured in platelet extracts
using an established HPLC method. Briefly, platelet suspen-
sions (normalised to 150×103/μl) were lysed before disulfide
reduction, achieved by the addition of reducing agent (10%
tri-butyl phosphine in dimethylformamide; 4°C for 30 min).
Samples were deproteinised by the addition of 150 μl tri-
chloroacetic acid (10% in 1 mmol/l EDTA), vortexed (20 s),
then centrifuged (8,000 g, 5 min, 4°C). One-hundred micro-
litres of the supernatant fraction was prepared for derivatisa-
tion by the addition of 20 μl of 1.55 mol/l sodium hydroxide,
250 μl of 0.125 mol/l borate buffer (pH 9.5) and 100 μl of
1 mg/ml ammonium 7-fluoro-2,1,3-benzoxadiazole-4-sulfo-
nate (SBD-F). Samples were vortexed briefly and incubated
(60°C, 1 h). Cooled samples were analysed by HPLC (Agilent
1200 series; Agilent Technologies, Stockport, UK) using
Table 2 Clinical management regimens for study patients
Treatment No. of patients
Diet alone 4
Metformin alone 3
Metformin+sulfonylurea 3
Metformin+sulfonylurea+glitazone 3
Sulfonylurea alone 1
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fluorescence detection (excitation λ0385 nm, emission λ0515
nm). Chromatographic separations were achieved with a
Gemini-NX C18 column (250 mm×4.6 mm×5 μm; Phenom-
enex,Macclesfield, UK) and amobile phase of 7% acetonitrile,
93% 100 mmol/l KH2PO4 at pH 2.1. Forty-microlitre samples
were injected onto the column and eluted at a flow rate of 1 ml/
min. Thiol derivatives were quantified using peak areas. Pro-
tein concentrations in extracts were quantified using a Coo-
massie protein assay (Perbio Science, Cramlington, UK).
Plasma NAC measurement Total NAC (i.e. oxidised+
reduced) was measured in deproteinised plasma using HPLC
with fluorescence detection (as above) according to a method
adapted from that of Wilkinson et al [28].
Statistical power A review of the literature pertaining to the
various assays conducted in this project identified platelet–
monocyte conjugation as the least powerful technique used in
this study. The power calculation was therefore conducted for
this measure: for a significance level of p00.01 and a power of
80% for detecting a change in platelet–monocyte conjugation
of 10%, 15 individuals were recruited to the study.
Statistical analyses Patient characteristics are expressed as
mean ± SD; all other results are expressed as mean±SEM.
Curve fitting and statistical tests were performed using
GraphPad Prism software (version 5.00; Graphpad, San
Diego, CA, USA). Data distribution was assessed using
the Kolmogorov–Smirnov test. All data sets followed
Gaussian distribution. It was therefore appropriate to use
parametric statistics: t tests, two-way ANOVAwith repeated
measures and Pearson’s correlation tests were used, as
appropriate. p<0.05 was considered to be statistically
significant.
Drugs, chemicals, reagents and other materials The inves-
tigational product (NAC) and placebo tablets were supplied
by Tayside Pharmaceuticals (Dundee, UK). CD14-FITC
(BD 555397), IgG2a-FITC (BD 555573), CD41-PE-Cy5
(BD 559768), IgG1-PE-Cy5 (BD 555750) and FACS lysing
solution were all obtained from Becton Dickinson. Polysty-
rene latex beads (3μm) were purchased from Sigma Aldrich
(Poole, UK). ELISA kits for the measurement of PAI-1 anti-
gen and activity were from Hyphen BioMed (Paris, France).
Results
Participant characteristics The characteristics of the study
population are shown in Tables 1 and 2. One patient
reported feeling nauseous at times between the two visits
on the NAC arm of the study but no other adverse reactions
were noted. It was not possible to obtain a blood sample
from one of the patients after placebo administration at their
first visit so data from this patient was excluded from the
majority of the analyses. There was insufficient platelet
extract for GSH analysis in samples from two further
patients.
Platelet–monocyte conjugation Platelet–monocyte conjuga-
tion was significantly inhibited in patients at 2 h after ad-
ministration of NAC (conjugated monocytes reduced from
53.1±4.5 to 42.5±3.9% of monocyte population: p00.011;
Fig. 2a); no significant effect was seen in the equivalent
0 1 2 3 4Study day: 5
Fast
2h
1,200mg
NAC/placebo
6 7
Conjugates
Microparticles
PAI-1
NAC
Fast
Blood draw Blood drawPlasma
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Microparticles
Fresh
Flow
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Fig. 1 Diagrammatic
representation of the study
design
Diabetologia (2012) 55:2920–2928 2923
results from the placebo arm of the study (p>0.05; Fig. 2b).
Baseline-subtracted data indicate that depression of platelet–
monocyte conjugation was maintained (approximately −10
to –15% compared with placebo) on day 7 of once-daily
administration of NAC, both before and after the final
administration (Fig. 2c; p00.035; two-way ANOVA).
Microparticles In the NAC arm of the study there was a
trend towards depression of plasma-borne microparticles
that did not reach significance (–31%; p00.094; Fig. 3a);
microparticles were significantly (+25%; p00.048) elevated
at 2 h after placebo administration (Fig. 3b).Baseline-sub-
tracted data indicate that this pattern of effect was main-
tained at day 7 after daily oral dosing; the depression of
microparticles in the NAC arm compared with the placebo
arm of the study was significant (Fig. 3c; p<0.016).
Plasma NAC Plasma NAC was only detectable in 8/14
patients (1–2 μmol/l) at 2 h after NAC administration. No
residual NAC was measured at baseline on the second visit
(i.e. ∼24 h after the final self-administered dose; threshold
for detection, 1 μmol/l).
Plasma PAI-1 There was no significant effect of NAC or
placebo on plasma PAI-1 antigen or activity at either 2 h
after the first dose or after 7 days of oral dosing (p>0.05).
Intraplatelet tGSH Intraplatelet tGSH was not significantly
altered in either the NAC or placebo arms of the study at
+2 h (Fig. 4 a,b). However, there was a clear association
between the effect of NAC on tGSH after 2 h and the
baseline pre-NAC tGSH that was not seen in the placebo
arm (Fig. 4c). Subsequent subgrouping of patients into those
with baseline platelet tGSH >120 nmol/mg protein (‘GSH
replete’) and those below this cut-off (‘GSH deficient’),
clearly shows that NAC is only effective in enhancing tGSH
in the group that is GSH deficient (Fig. 4d). This effect was
not seen in the same subgroupings after placebo (Fig. 4e).
There was no association between plasma NAC detection
and either change in platelet–monocyte conjugation or intra-
platelet tGSH (data not shown).
Association of baseline intraplatelet tGSH or HbA1c with
platelet–monocyte conjugation Platelet–monocyte conjuga-
tion was inversely correlated with baseline intraplatelet
Fig. 2 Effect of NAC (a; p00.011; n014 by paired Student’s t test)
and placebo (b; p>0.05) on platelet–monocyte conjugation after 2 h
and after 7 days of daily oral dosing (c; p00.010 for NAC vs placebo;
n013 by repeated measures two-way ANOVA). NAC, but not placebo,
was found to reduce platelet–monocyte conjugation at 2 h after oral
dosing and the reduction compared with placebo was significant across
the 7 day dosing period (black bars, NAC; white bars, placebo.)
Insufficient blood was drawn from one patient at one visit and data
from that patient was excluded from (c)
Fig. 3 Effect of NAC (a) and placebo (b) on plasma microparticle
count after 2 h. There was a significant increase in microparticle count
at 2 h in the placebo arm of the study (p00.047 by paired Student’s t
test) but a trend towards a reduction (p00.09) in the NAC arm (n014).
Over a 7 day dosing period (c), there was a significant inhibition of
microparticle count between NAC and placebo (black bars, NAC;
white bars, placebo: p00.016 for NAC vs placebo; n013 by repeated
measures two-way ANOVA) Insufficient blood was drawn from one
patient at one visit and data from that patient was excluded from (c)
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tGSH (Fig. 5a), but not with HbA1c (Fig. 5b), in participants
in this study.
Discussion
This double-blind, randomised, placebo-controlled crossover
study provides evidence, for the first time, that oral dosing
with NAC effectively inhibits platelet–monocyte conjugation
and microparticle count in patients with well-controlled type 2
diabetes. The extent of the effect on intraplatelet GSH was
inversely correlated with baseline intraplatelet GSH and, un-
like HbA1c, baseline intraplatelet GSH was also inversely
correlated with baseline platelet–monocyte conjugation.
Platelet–monocyte conjugation is gaining recognition
as an effective marker for cardiovascular risk [29–32].
Fig. 4 Effect of NAC on intraplatelet GSH. Neither NAC (a) nor
placebo (b) had a significant impact on platelet GSH (p>0.05 for both;
n012). There was, however, a significant negative correlation between
the NAC-induced increase in platelet tGSH at 2 h and the baseline tGSH
(c: black symbols; p00.0007, r00.82, r200.66; n012), which was not
reproduced in the placebo arm (white symbols; p00.97, r00.01, r20
0.0002; n012). The level at whichNAC had no effect was estimated to be
120 nmol GSH/mg protein (c: dotted line; this value was used to
subdivide patients into tGSH replete (>120 nmol/mg protein) and defi-
cient <120 nmol/mg protein) for further analysis (d, e). Subgroup analysis
for individuals with baseline tGSH of <120 nmol/mg protein (black bar;
n06) and those above this value (white bar; n06) clearly showed that GSH is
only increased by NAC administration in those with depleted GSH (d: *p<
0.05; **p<0.01;***p<0.001 ); placebo failed to show the same trend
(e) Insufficient sample was available from two patients for GSH
analysis
Fig. 5 Correlation between baseline tGSH (a) and HbA1c (b) and
platelet–monocyte conjugation (%). There was a significant negative
correlation between tGSH (p00.047, r00.58, r200.34; n012) and
platelet–monocyte conjugation (a) but no correlation between HbA1c
and platelet–monocyte conjugation (b: p00.225, R00.044, r200.05;
n014). To convert values for HbA1c in % to mmol/mol, subtract 2.15
and multiply by 10.929. Insufficient sample was available from two
patients for GSH analysis
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Elevated platelet–monocyte conjugation is indicative of an
increased level of circulating platelet activation, which
might predispose to thrombus. Moreover, conjugation of
activated platelets to monocytes propagates activation of
the monocytes themselves [33], increasing the potential for
monocyte interaction with the endothelium [34], an early
critical event in the atherogenic process [35]. A number of
antiplatelet agents [36–38] have been shown to depress
platelet–monocyte conjugate formation. Circulating micro-
particles are cell-derived vesicles that are likewise gaining
credence as possible markers of cardiovascular risk because
of their elevated levels in a range of cardiovascular
conditions [39–43]. While their precise role is still to
be fully determined, they appear to be associated with
tissue factor and might play a role in thrombosis. On
this basis, we selected platelet–monocyte conjugates and
microparticles as the principal outcome measures for
this study.
Both platelet–monocyte conjugate and microparticle
measures are depressed by NAC compared with placebo
within 2 h of administration and the effect is maintained at
day 7 following once-daily dosing on the intervening days.
The rapidity of onset of the effect on both markers is
perhaps surprising, particularly in light of the fact that
NAC is undetectable at the 2 h time point in 6/14 individ-
uals. However, given the known rapidity of both NAC
absorption (time to peak (tmax) 0.5–3 h) and incorporation
into cellular GSH (tmax ∼1 h), coupled with the wide vari-
ability in pharmacokinetics of the drug (t1/2 1.4–3.9 h) [20],
both the speed of response and the variability in NAC
detection at 2 h are explicable. In the case of platelet–
monocyte conjugates, the results indicate that conjugation
is a highly dynamic two-way process, the balance of which
is disturbed by NAC in favour of disaggregation. With
respect to the microparticle data, the results are more com-
plex: at least part of the significant effect of NAC on micro-
particles is due to prevention or reversal of an increase in
microparticle count seen in the placebo arm of the study.
The driver for this pro-microparticle effect is unknown, but
it might be a simple time-mediated event or could be pre-
cipitated by the light breakfast taken by participants between
samples. The microparticles measured in this study are not
characterised and could therefore be derived from inflam-
matory or endothelial cells as well as platelets. Further
exploratory work is required to identify the driving force
behind the change in microparticle effect and how NAC
inhibits this process.
Plasma PAI-1 was not affected by NAC at any of the time
points measured. PAI-1 was measured because a previous
clinical study using injected GSH [13] had found that plas-
ma PAI-1 was reduced after treatment. The inference from
our finding is that the effect found previously is specific to
plasma GSH as opposed to intracellular GSH. Neither
plasma NAC nor the increased intraplatelet tGSH, found
in at least a cohort of our test group, significantly influenced
PAI-1 antigen or activity.
The impact of oral NAC on intraplatelet tGSH was not as
clear cut as we had found previously in vitro [26, 27]. While
the tGSH in the placebo arm was reassuringly consistent,
that in the NAC arm showed no change in terms of mean
value, but revealed a striking pattern of effect that was
dependent on the baseline tGSH: low baseline was asso-
ciated with a large increase, high baseline with either no
change or a small decrease. The association was borne
out by correlation analysis from which, despite the rela-
tively small sample size, there was found to be a clear
inverse correlation between NAC effect size and baseline
tGSH, which was not seen in the placebo arm of the
study. We used a linear regression plot to estimate the
baseline tGSH level that determines likely ‘responders’
(tGSH deficient) from ‘non-responders’ (tGSH replete;
>120 nmol/mg protein). Retrospective subgroup analysis
of responders and non-responders confirmed that tGSH
was only significantly increased by NAC in the depleted
group.
The consequence of this finding is that NAC is only
likely to have a biochemical impact in those patients with
depleted tGSH (on the evidence of this study, ∼50% of
patients with well-controlled type 2 diabetes). The addition-
al finding that there was an inverse association between
tGSH and platelet–monocyte conjugation, suggests that
tGSH depletion might be an effective marker of cardiovas-
cular risk. Certainly, the correlation between these factors is
much clearer than that between HbA1c and platelet–mono-
cyte conjugation, albeit that the patients in this study had
relatively well-controlled type 2 diabetes. Furthermore,
were low intraplatelet tGSH to be causal in heightened
platelet activation in type 2 diabetes, there is the tantalising
possibility that NAC administration is most effective in
those individuals who are most at risk of cardiovascular
complications. This is a novel finding that, if confirmed
in a larger study, could point not only to depleted GSH
as a contributory factor in heightened platelet activation
in type 2 diabetes, but also to the usefulness of intra-
cellular GSH screening before NAC therapy. A critical
role for intracellular GSH in determining the extent of
NAC benefit might also explain the lack of consistency
in results from studies in a range of clinical conditions
[15–21], where intracellular GSH has not been a
consideration.
In summary, the results of this study indicate that once-
daily oral administration of NAC holds promise in primary
prevention of cardiovascular complications associated with
type 2 diabetes. These features, together with known bene-
fits with respect to hypertension [24] and endothelial func-
tion [23], extend the possible therapeutic targets for NAC
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beyond the confines of type 2 diabetes; patients with meta-
bolic syndrome and other cardiovascular conditions in
which oxidative stress and GSH depletion feature might
also benefit.
The ability of NAC to reduce platelet–monocyte conju-
gation is linked to the degree of platelet tGSH depletion, a
selective property that might effectively target those at high-
est risk of cardiovascular complications. In the impending
era of personalised medicine, patients most likely to benefit
from NAC administration could be identified through plate-
let tGSH measurement in a blood sample taken before
treatment.
A limitation of this study is that it focused on patients
with mainly well-controlled type 2 diabetes (mean HbA1c
6.9±0.9% [52.3±10.3 mmol/mol]). It would therefore be
interesting to establish whether similar findings relate to
patients with poorer glycaemic control. It is also important
to establish whether specific diabetes therapies, such as
insulin, impact on platelet–monocyte conjugation, intrapla-
telet tGSH and the effects of NAC; this would have espe-
cially important implications with respect to the relevance of
this potential therapy in type 1 diabetes. Finally, the effects
have only been determined over a relatively short period (8
days). The impact of chronic therapy requires investigating
to confirm that the beneficial effects are maintained through-
out a much longer intervention period. The study, though
relatively small, was adequately powered for the outcome
measures.
In conclusion, this study is the first of its kind to show
that oral NAC therapy has the potential to reduce cardio-
vascular risk in those patients with type 2 diabetes who have
depleted intraplatelet GSH. There currently exists a paradox
in the primary prevention of cardiovascular disease in dia-
betes: while diabetes is known to increase cardiovascular
risk, the principal antiplatelet agent, aspirin, has been found
to be ineffective in this patient group and is no longer
recommended. This leaves diabetes patients untreated and
without an efficacious antiplatelet choice. The current find-
ing is timely in that NAC might represent part of the solu-
tion for an unprotected patient population. The results also
highlight the importance of individualised therapy for
patients with diabetes: NAC may only be effective in that
subset of the patient population with type 2 diabetes who
are deficient in intracellular GSH. However, the likely
effectiveness of the treatment could be screened for in
advance through measurement of intraplatelet GSH. In
addition, the likely link between oxidative stress, GSH
depletion and cardiovascular risk might mean that NAC
treatment will target those most vulnerable to cardiovas-
cular disease. An outcome study is now merited to
confirm that reduction in platelet–monocyte conjugates
is reflected in a reduction in cardiovascular events in this
patient group.
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